

## FITC anti-mouse F4/80 Antibody

|                          |   |
|--------------------------|---|
| <b>Catalog# / Size</b>   | 123107 / 50 µg<br>123108 / 500 µg   |
| <b>Clone</b>             | BM8   |
| <b>Regulatory Status</b> | RUO   |
| <b>Other Names</b>       | EMR1, Ly71  |
| <b>Isotype</b>           | Rat IgG2a, κ  |
| <b>Description</b>       | F4/80 is a 160 kD glycoprotein. It is characterized as a member of the epidermal growth factor (EGF)-transmembrane 7 (TM7) family. F4/80, also known as EMR1 or Ly71, has been widely used as a murine macrophage marker, which is expressed on the majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen (but not on the macrophages located in T cell areas of the spleen, lymph node and Peyer's patch), Kuffer cells, Langerhans cells, and bone marrow stromal cells. F4/80 has also been shown on a subset of dendritic cells. The biological ligand of F4/80 has not been identified, but it has been reported that F4/80 is required for induction of CD8 <sup>+</sup> T cell-mediated peripheral tolerance. |

### Product Details

---

|   |   |
|---|---|
| <b>Verified Reactivity</b>                        | Mouse   |
| <b>Antibody Type</b>                              | Monoclonal  |
| <b>Host Species</b>                               | Rat   |
| <b>Immunogen</b>                                  | Murine macrophages  |
| <b>Formulation</b>                                | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.   |
| <b>Preparation</b>                                | The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.  |
| <b>Concentration</b>                              | 0.5 mg/ml   |
| <b>Storage &amp; Handling</b>                     | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>   |
| <b>Application</b>                                | <a href="#">FC - Quality tested</a>   |
| <b>Recommended Usage</b>                          | Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.  |
| <b>Excitation Laser</b>                           | Blue Laser (488 nm)   |
| <b>Application Notes</b>                          | Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections <sup>1,2</sup> and formalin-fixed paraffin-embedded sections <sup>6,7</sup> , Western blotting, and spatial biology (IBEX) <sup>12,13</sup> .  |
| <b>Application References</b>                     | <ol style="list-style-type: none"> <li>Schaller E, <i>et al.</i> 2002. <i>Mol. Cell. Biol.</i> 22:8035. (IHC)</li> <li>Stevceva L, <i>et al.</i> 2001. <i>BMC Clin Pathol.</i> 1:3. (IHC)</li> <li>Kobayashi M, <i>et al.</i> 2008. <i>J. Leukoc. Biol.</i> 83:1354. <a href="#">PubMed</a></li> <li>Poeckel D, <i>et al.</i> 2009. <i>J. Biol Chem.</i> 284:21077. <a href="#">PubMed</a></li> <li>Glass AM, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:4830. <a href="#">PubMed</a></li> <li>Koehm S, <i>et al.</i> 2007. <i>J. Allergy Clin. Immunol.</i> 120:570. (IHC)</li> <li>Rankin AL, <i>et al.</i> 2010. <i>J. Immunol.</i> 184:1526. (IHC)</li> <li>Sasi SP, <i>et al.</i> 2014. <i>J Biol Chem.</i> 289:14178. <a href="#">PubMed</a></li> <li>Thakus VS, <i>et al.</i> 2014. <i>Toxicol Lett.</i> 230:322. <a href="#">PubMed</a></li> <li>Watson NB, <i>et al.</i> 2015. <i>J Immunol.</i> 194:2796. <a href="#">PubMed</a></li> <li>Hirakawa H, <i>et al.</i> 2015. <i>PLoS One.</i> 10:119360. <a href="#">PubMed</a></li> </ol> |
| <b>(PubMed link indicates BioLegend citation)</b> |   |

12. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
13. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Jiang L, *et al.* 2013. *Mol Immunol.* 54:14. [PubMed](#)
2. Liu K, *et al.* 2021. *Cell Metabolism.* 33(3):666-675.e4. [PubMed](#)
3. Liu J, *et al.* 2019. *Immunity.* 50:600. [PubMed](#)
4. Xiong Y, *et al.* 2020. *J Nanobiotechnology.* 18:66. [PubMed](#)
5. Wang L, *et al.* 2008. *Cancer Res.* 68:5639. [PubMed](#)
6. Jiang Z, *et al.* 2021. *J Clin Invest.* 131: . [PubMed](#)
7. Vasanthakumar A, *et al.* 2020. *Nature.* 579:581. [PubMed](#)
8. Liang J, *et al.* 2021. *Cancer Manag Res.* 13:6977. [PubMed](#)
9. Li F, *et al.* 2022. *Mediators Inflamm.* 2022:5782922. [PubMed](#)
10. Wang HH, *et al.* 2022. *J Biomed Sci.* 29:36. [PubMed](#)
11. Zheng M, *et al.* 2016. *Sci Rep.* 6:28729. [PubMed](#)
12. Marcil A, *et al.* 2008. *Infect Immun.* 76:4345. [PubMed](#)
13. Kimura H, *et al.* 2017. *J Immunol.* 10.4049/jimmunol.1601798. [PubMed](#)
14. Chen Y, *et al.* 2018. *EBioMedicine.* 32:31. [PubMed](#)
15. Zhang Y, *et al.* 2018. *Sci Rep.* 8:5994. [PubMed](#)
16. Barry KC, *et al.* 2018. *Nat Med.* 24:1178. [PubMed](#)
17. Chou YJ, *et al.* 2020. *Sci Rep.* 10:8422. [PubMed](#)
18. Hsu SPC, *et al.* 2020. *J Neurooncol.* 146:417. [PubMed](#)
19. Morgan PK, *et al.* 2021. *J Biol Chem.* 297:101341. [PubMed](#)
20. Hewitson JP, *et al.* 2020. *J Immunol.* 204:2949. [PubMed](#)
21. Yang W, *et al.* 2020. *Nat Commun.* 3.553472222. [PubMed](#)
22. Mouton AJ, *et al.* 2018. *Basic Res Cardiol.* 113:26:00. [PubMed](#)
23. Lee Y, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0183028. [PubMed](#)
24. Stubelius A, *et al.* 2017. *Immunobiology.* 10.1016/j.imbio.2017.05.007. [PubMed](#)
25. Zhang L, *et al.* 2022. *Acta Pharm Sin B.* 12:3427. [PubMed](#)
26. Zhou X, *et al.* 2022. *Front Pharmacol.* 13:887263. [PubMed](#)
27. Chauhan A, *et al.* 2020. *Nat Commun.* 11:1939. [PubMed](#)
28. Rogic A, *et al.* 2021. *Nat Commun.* 12:6889. [PubMed](#)
29. Gu T, *et al.* 2021. *Front Immunol.* 11:621441. [PubMed](#)
30. Ohtsuki T, *et al.* 2016. *J Virol.* 90: 300 - 307. [PubMed](#)
31. Pan H, *et al.* 2020. *Mol Psychiatry.* . [PubMed](#)
32. Qiu X, *et al.* 2019. *Theranostics.* 9:2618. [PubMed](#)
33. Brunner JS, *et al.* 2020. *Nat Commun.* 0.757638889. [PubMed](#)
34. Alvarez M, *et al.* 2020. *Cancers (Basel).* 12: . [PubMed](#)
35. Shi S, *et al.* 2020. *Clin Cancer Res.* 26:5990. [PubMed](#)
36. Wang Y, *et al.* 2020. *J Immunol.* 205:2905. [PubMed](#)
37. Zhou HF, *et al.* 2022. *Front Pharmacol.* 13:778755. [PubMed](#)
38. Xiong A, *et al.* 2022. *EBioMedicine.* 83:104239. [PubMed](#)
39. Royzman D, *et al.* 2022. *Front Immunol.* 13:1012647. [PubMed](#)
40. Ostendorf BN, *et al.* 2020. *Nat Med.* 26:1048. [PubMed](#)
41. An YA *et al.* 2017. *eLife.* 6 pii: e24071. [PubMed](#)
42. Wang Y, *et al.* 2022. *Front Immunol.* 13:767630. [PubMed](#)
43. Kedage V, *et al.* 2022. *MAbs.* 14:2040083. [PubMed](#)
44. Xu X, *et al.* 2021. *J Nanobiotechnology.* 19:376. [PubMed](#)
45. Ma YV, *et al.* 2021. *MAbs.* 13:2003281. [PubMed](#)
46. Dichtl S, *et al.* 2021. *Sci Adv.* 7: . [PubMed](#)
47. Klopfenstein N, *et al.* 2021. *PLoS Pathog.* 17:e1009387. [PubMed](#)
48. Xiao Z, *et al.* 2015. *Cancer Lett.* 360:302. [PubMed](#)
49. Velázquez K, *et al.* 2016. *Am J Physiol Gastrointest Liver Physiol.* 311: G699 - G712. [PubMed](#)
50. Ratitong B, *et al.* 2021. *Cell Reports.* 35(7):109139. [PubMed](#)
51. Nakazeki F, *et al.* 2018. *Sci Rep.* 8:8553. [PubMed](#)
52. Barger SR, *et al.* 2019. *Nat Commun.* 10:1249. [PubMed](#)
53. Zhang S, *et al.* 2019. *Mol Med Rep.* 19:5377. [PubMed](#)
54. Dan H, *et al.* 2020. *Mol Oncol.* 14:795. [PubMed](#)
55. García-Bonilla M, *et al.* 2020. *Stem Cell Res Ther.* 11:121. [PubMed](#)
56. Niss K, *et al.* 2020. *Cell Reports.* 31(11):107763. [PubMed](#)
57. Wang F, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 13:257. [PubMed](#)
58. Xiao P, *et al.* 2021. *JCI Insight.* 6: . [PubMed](#)
59. Zheng Y, *et al.* 2022. *Front Pharmacol.* 12:816032. [PubMed](#)
60. Jing L, *et al.* 2022. *Front Immunol.* 13:864995. [PubMed](#)
61. Zhang X, *et al.* 2021. *Front Immunol.* 12:680068. [PubMed](#)
62. Zhang Y, *et al.* 2022. *Nat Commun.* 13:4553. [PubMed](#)
63. Geng T, *et al.* 2022. *Methods Mol Biol.* 2585:71. [PubMed](#)
64. Zhao X, *et al.* 2014. *J Biol Chem.* 289:30052. [PubMed](#)
65. Suo J, *et al.* 2014. *J Leukoc Biol.* 96:133. [PubMed](#)
66. Bignami F, *et al.* 2017. *Acta Ophthalmol.* 95:e641. [PubMed](#)
67. Yu H, *et al.* 2022. *J Orthop Surg Res.* 17:232. [PubMed](#)
68. Feng T, *et al.* 2022. *Nat Commun.* 13:5208. [PubMed](#)
69. Gu Y, *et al.* 2021. *Cell Res.* Online ahead of print. [PubMed](#)
70. Kornstädt L, *et al.* 2021. *Front Immunol.* 11:607048. [PubMed](#)
71. Odkhue E, *et al.* 2014. *Innate Immunity.* 21:194. [PubMed](#)
72. Lu X, *et al.* 2016. *Nat Commun.* 7: 12719. [PubMed](#)
73. Xie Z, *et al.* 2020. *Light Sci Appl.* 0.486805556. [PubMed](#)
74. Omori S, *et al.* 2021. *Cell Reports.* 34(6):108734. [PubMed](#)
75. DeVito NC, *et al.* 2021. *Cell Reports.* 35(5):109071. [PubMed](#)

76. Proto JD *et al.* 2018. *Immunity*. 49(4):666-677 . [PubMed](#)
77. Wu W, *et al.* 2018. *J Am Soc Nephrol*. 29:168. [PubMed](#)
78. Niemann J, *et al.* 2019. *Nat Commun*. 10:3236. [PubMed](#)
79. Rashidi M, *et al.* 2019. *J Immunol*. 203:736. [PubMed](#)
80. Duan RN, *et al.* 2021. *J Neuroinflammation*. 18:145. [PubMed](#)
81. Wang J, *et al.* 2021. *Nat Commun*. 12:6198. [PubMed](#)
82. Wang Y, *et al.* 2021. *EMBO J*. 40:e105543. [PubMed](#)
83. Barsoumian HB, *et al.* 2020. *J Immunother Cancer*. 8:00. [PubMed](#)
84. Vettorazzi S, *et al.* 2015. *Nat Commun*. 6: 7796. [PubMed](#)
85. Miki Y, *et al.* 2013. *J Exp Med*. 210:1217. [PubMed](#)
86. Linde N, *et al.* 2012. *PLoS One*. 7:e40058. [PubMed](#)
87. Moon H, *et al.* 2020. *Nat Commun*. 4.270138889. [PubMed](#)
88. Wan X, *et al.* 2018. *Nature*. 560:107. [PubMed](#)
89. Niknam S, *et al.* 2018. *Clin Cancer Res*. 24:5735. [PubMed](#)
90. Tavazoie MF, *et al.* 2018. *Cell*. 172:825. [PubMed](#)
91. Yu Y, *et al.* 2018. *Mol Med Rep*. 17:8212. [PubMed](#)
92. Irie Y, *et al.* 2017. *J Neuroimmune Pharmacol*. 10.1007/s11481-017-9757-2. [PubMed](#)
93. Wang H, *et al.* 2022. *J Nanobiotechnology*. 20:445. [PubMed](#)
94. Wang Y, *et al.* 2022. *Cell Death Dis*. 13:748. [PubMed](#)
95. Wu Y, *et al.* 2021. *PLoS Negl Trop Dis*. 15:e0010050. [PubMed](#)
96. Lewis EL, *et al.* 2021. *Front Immunol*. 12:741518. [PubMed](#)
97. Cai C, *et al.* 2021. *Sci Rep*. 11:13386. [PubMed](#)
98. Artz A, Butz S, Vestweber D 2016. *Am J Physiol Renal Physiol*. 311: F176 - F181. [PubMed](#)
99. Abe M, *et al.* 2020. *Clin Exp Immunol*. 303:199. [PubMed](#)
100. Matsumoto K, *et al.* 2017. *PLoS One*. 12(6):e0175406. [PubMed](#)
101. Van Winkle JA *et al.* 2018. *Cell host & microbe*. 24(5):665-676 . [PubMed](#)
102. Martínez-López M *et al.* 2019. *Immunity*. 50(2):446-461 . [PubMed](#)
103. Liu S, *et al.* 2020. *Cell Host & Microbe*. 26(6):779-794.e8.. [PubMed](#)
104. Kasahara D, *et al.* 2012. *J Immunol*. 188:4558. [PubMed](#)
105. Zhu Y, *et al.* 2021. *EMBO J*. 40:e105320. [PubMed](#)
106. Macháček T, *et al.* 2022. *PLoS Pathog*. 18:e1010302. [PubMed](#)
107. Qin W, *et al.* 2021. *FASEB J*. 35:e21599. [PubMed](#)
108. Zhang Q, *et al.* 2022. *Nat Commun*. 13:2406. [PubMed](#)
109. Koikawa K, *et al.* 2021. *Cell*. 184(18):4753-4771.e27. [PubMed](#)
110. Parayath NN, *et al.* 2020. *Nat Commun*. 4.680555556. [PubMed](#)
111. Arce-Cerezo A, *et al.* 2015. *Sci Rep*. 5: 1448. [PubMed](#)
112. Torres I, *et al.* 2014. *Infect Immun* . 82:4689. [PubMed](#)
113. Deng G, *et al.* 2010. *J Immunol*. 184:7154. [PubMed](#)
114. Coronel MM, *et al.* 2020. *Sci Adv*. 6:eaba5573. [PubMed](#)
115. Stifter SA, *et al.* 2019. *Cell Rep*. 29:3539. [PubMed](#)
116. Tomay F, *et al.* 2019. *J Transl Med*. 17:237. [PubMed](#)
117. Zheng X, *et al.* 2018. *J Clin Invest*. 128:2104. [PubMed](#)
118. Fan Q, *et al.* 2021. *Bioact Mater*. 6:4014. [PubMed](#)
119. Patankar Y, *et al.* 2015. *Am J Physiol Lung Cell Mol Physiol*. 309: L902 - L913. [PubMed](#)
120. Uematsu T, *et al.* 2016. *Sci Rep*. 6:37815. [PubMed](#)
121. Taye B, *et al.* 2017. *BMC Genomics* . 10.1186/s12864-017-3803-6. [PubMed](#)
122. Wang Y *et al.* 2017. *Cell*. 171(2):331-345 . [PubMed](#)
123. Subramanian K, *et al.* 2019. *Nat Microbiol*. 4:62. [PubMed](#)
124. Hou PP, *et al.* 2020. *Molecular Cell*. 78(6):1192-1206.e10. [PubMed](#)
125. Sasaki Y, *et al.* 2015. *PLoS One*. 10: 0131176. [PubMed](#)
126. Honda H, *et al.* 2014. *J Leukoc Biol*. 96:1087. [PubMed](#)
127. Drori A, *et al.* 2014. *PLoS One*. 9:110942. [PubMed](#)
128. Quick M, *et al.* 2012. *Am J Physiol Regul Integr Comp Physiol*. 303:580. [PubMed](#)
129. Lu SW, *et al.* 2020. *Nat Commun*. 3.660416667. [PubMed](#)
130. Fukushima K, *et al.* 2020. *Immunity*. 52(3):542-556. [PubMed](#)
131. Li YT, *et al.* 2019. *Elife*. 8:e47642. [PubMed](#)
132. Baomei Wang *et al.* 2019. *Cell reports*. 26(6):1614-1626 . [PubMed](#)
133. Du H, *et al.* 2017. *Nat Commun*. 10.1038/s41467-017-00522-7. [PubMed](#)
134. Nenasheva T, *et al.* 2017. *PLoS One*. 12(6):e0178983. [PubMed](#)
135. Howard ZM, *et al.* 2022. *JCI Insight*. 7:. [PubMed](#)
136. Miki Y, *et al.* 2022. *JCI Insight*. 7:. [PubMed](#)
137. Anderson-Baucum E, *et al.* 2021. *Cell Metab*. 33:1883. [PubMed](#)
138. Raouf R, *et al.* 2021. *J Neurosci*. 41:8249. [PubMed](#)
139. Wang X, *et al.* 2022. *J Biol Chem*. 298:101561. [PubMed](#)
140. Yuan M, *et al.* 2022. *Oxid Med Cell Longev*. 2022:5479491. [PubMed](#)
141. Chen Z, *et al.* 2016. *PLoS One*. 11: 0146681. [PubMed](#)
142. Mothes B, *et al.* 2016. *PLoS One*. 11: 0159310. [PubMed](#)
143. Yuan Y, *et al.* 2020. *Front Physiol*. 0.967361111. [PubMed](#)
144. Bordas M, *et al.* 2020. *Int J Mol Sci*. 21:00. [PubMed](#)
145. Lv JJ, *et al.* 2021. *Front Cell Dev Biol*. 8:609090. [PubMed](#)
146. Yan T, *et al.* 2021. *Toxicological Sciences*. 181(2):273-284. [PubMed](#)
147. Dongsheng Z, *et al.* 2017. *Inflammation*. 10.1007/s10753-017-0619-0. [PubMed](#)
148. Di G, *et al.* 2017. *Invest Ophthalmol Vis Sci*. 10.1167/iov.17-21506. [PubMed](#)
149. Xia Y, *et al.* 2018. *Cell*. 175:1059. [PubMed](#)
150. Osorio K, *et al.* 2011. *J Cell Biol*. 193:235. [PubMed](#)
151. Deng Q, *et al.* 2021. *Gut Microbes*. 13:1. [PubMed](#)
152. Glasenapp A, *et al.* 2021. *Circ Res*. 129:369. [PubMed](#)
153. Zheng X, *et al.* 2020. *Int J Cancer*. 146:1730. [PubMed](#)
154. Vaibhav K, *et al.* 2020. *Sci Adv*. 6:eaax8847. [PubMed](#)
155. Zhou T, *et al.* 2021. *Bioact Mater*. 0.734027778. [PubMed](#)

156. van Aalst S, *et al.* 2017. *Vaccine*. 10.1016/j.vaccine.2017.02.005. [PubMed](#)
157. Meunier I, *et al.* 2015. *PLoS One*. 10: 0138055. [PubMed](#)
158. Nasser H, *et al.* 2020. *Cell Death Discov*. 0.29375. [PubMed](#)
159. Clemente-Casares X, *et al.* 2017. *Immunity*. 47:974. [PubMed](#)
160. Lu Q, *et al.* 2022. *Biomed Res Int*. 2022:9427076. [PubMed](#)
161. Nam J, *et al.* 2021. *Adv Ther (Weinh)*. 4: [PubMed](#)
162. Howard ZM, *et al.* 2021. *Am J Pathol*. 191:730. [PubMed](#)
163. Li Y, *et al.* 2020. *Theranostics*. 10:2897. [PubMed](#)
164. Zhao H, *et al.* 2022. *Commun Biol*. 5:74. [PubMed](#)
165. Lee SA, *et al.* 2021. *Cells*. 10: [PubMed](#)
166. Elias I, *et al.* 2012. *Diabetes*. 61:1801. [PubMed](#)
167. Schaffert S, *et al.* 2015. *J Immunol*. 195: 1470-1479. [PubMed](#)
168. Porrello A, *et al.* 2018. *Nat Commun*. 9:1988. [PubMed](#)
169. Lancaster GI *et al.* 2018. *Cell metabolism*. 27(5):1096-1110 . [PubMed](#)
170. Lang JF *et al.* 2019. *Nat Commun*. 10(1):3415 . [PubMed](#)
171. Yoshida H, *et al.* 2019. *Cell*. 176:897. [PubMed](#)
172. Kataru RP, *et al.* 2019. *Cancer Immunol Res*. 7:1345. [PubMed](#)
173. Vazquez-Lombardi R, *et al.* 2017. *Nat Commun*. 8:15373. [PubMed](#)
174. Morein D, *et al.* 2021. *Cells*. 10: [PubMed](#)
175. Sakurai Y, *et al.* 2021. *Pharmaceutics*. 13: [PubMed](#)
176. Zhang F, *et al.* 2021. *J Immunol Res*. 2021:5521051. [PubMed](#)
177. Liu C, *et al.* 2022. *Cell Death Discov*. 8:269. [PubMed](#)
178. Gautam S, *et al.* 2020. *Am J Physiol Lung Cell Mol Physiol*. 319:L661. [PubMed](#)
179. Mujal AM, *et al.* 2022. *Cancer Immunol Res*. 10:403. [PubMed](#)
180. Simoni L, *et al.* 2020. *Cell Rep*. 33:108330. [PubMed](#)
181. Martins R, *et al.* 2016. *Nat Immunol*. 17:1361-1372. [PubMed](#)
182. Kwon H, Kim S 2016. *Cell Death Dis*. 7:22285. [PubMed](#)
183. Zhang J, *et al.* 2020. *J Cell Mol Med*. 24:4547. [PubMed](#)
184. Rodriguez-Tirado C, *et al.* 2022. *Cancers (Basel)*. 14: [PubMed](#)
185. Fite BZ, *et al.* 2021. *Sci Rep*. 11:927. [PubMed](#)
186. Bringmann G, *et al.* 2013. *Antimicrob Agents Chemother*. 57:3003. [PubMed](#)
187. Tran S, *et al.* 2020. *Immunity*. 53(3):627-640.e5. [PubMed](#)
188. Goldberg EL, *et al.* 2021. *Cell Metabolism*. [PubMed](#)
189. Albaghdadi AJH, *et al.* 2019. *Sci Rep*. 9:6528. [PubMed](#)
190. Li B *et al.* 2019. *Cell reports*. 26(10):2720-2737 . [PubMed](#)
191. Li A, *et al.* 2018. *Cancer Lett*. 431:54. [PubMed](#)
192. Kurelac I, *et al.* 2019. *J Clin Med*. 1.85. [PubMed](#)
193. Krotova K, *et al.* 2019. *Mol Ther Oncolytics*. 15:166. [PubMed](#)
194. Bhatia S, *et al.* 2019. *Cancer Res*. 79:2722. [PubMed](#)
195. Lai NY, *et al.* 2020. *Cell*. 180:33:00. [PubMed](#)
196. Caetano MS, *et al.* 2019. *Clin Cancer Res*. 25:7576. [PubMed](#)
197. Guo Y, *et al.* 2021. *Nat Immunol*. 22:746. [PubMed](#)
198. Cortez MA, *et al.* 2020. *Nat Commun*. 3.819444444. [PubMed](#)
199. Uematsu T, *et al.* 2015. *Sci Rep*. 5: 17577. [PubMed](#)
200. Wegiel B, *et al.* 2014. *Cell Death Dis*. 5:1139. [PubMed](#)
201. Richardson M, *et al.* 2014. *PLoS Negl Trop Dis*. 8:2825. [PubMed](#)
202. Deniset JF *et al.* 2019. *Immunity*. 51(1):131-140 . [PubMed](#)
203. Kubli SP, *et al.* 2019. *Nat Commun*. 10:2678. [PubMed](#)
204. Song X, *et al.* 2022. *Transl Oncol*. 15:101306. [PubMed](#)
205. Zhong J, *et al.* 2021. *Commun Biol*. 4:865. [PubMed](#)
206. Xie Z, *et al.* 2020. *Light Sci Appl*. 9:161. [PubMed](#)
207. Yang F, *et al.* 2021. *Nat Commun*. 12:3424. [PubMed](#)

**RRID** AB\_893500 (BioLegend Cat. No. 123107)  
 AB\_893502 (BioLegend Cat. No. 123108)

## Antigen Details

---

|                           |  |
|---------------------------|--|
| <b>Structure</b>          | EGF-TM7 family member, 160 kD glycoprotein   |
| <b>Distribution</b>       | Majority of tissue macrophages including peritoneal macrophages, macrophages in lung, gut, thymus and red pulp of spleen, Kuffer cells, Langerhans cells, bone marrow stromal cells, and a subset of dendritic cells   |
| <b>Function</b>           | Induction of immunological tolerance   |
| <b>Cell Type</b>          | Dendritic cells, Langerhans cells, Macrophages, Tregs  |
| <b>Biology Area</b>       | Cell Biology, Immunology, Innate Immunity, Neuroinflammation, Neuroscience   |
| <b>Antigen References</b> | <ol style="list-style-type: none"> <li>1. Austy JM and Gordon S. 1981. <i>Eur. J. Immunol</i>. 11:805.</li> <li>2. Hume DA, <i>et al.</i> 1983. <i>J. Exp. Med</i>. 158:1522.</li> <li>3. Ruedl C, <i>et al.</i> 1996. <i>Eur. J. Immunol</i>. 26:1801.</li> <li>4. McKnight AJ, <i>et al.</i> 1996. <i>J. Biol. Chem</i>. 271:486.</li> <li>5. Lin HH, <i>et al.</i> 2005. <i>J. Exp. Med</i>. 201:1615.</li> </ol> |


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Brilliant Violet 605™ anti-mouse F4/80, Purified anti-mouse F4/80, Biotin anti-mouse F4/80, FITC anti-mouse F4/80, PE anti-mouse F4/80, PE/Cyanine5 anti-mouse F4/80, PE/Cyanine7 anti-mouse F4/80, APC anti-mouse F4/80, APC/Cyanine7 anti-mouse F4/80, Alexa Fluor® 488 anti-mouse F4/80, Alexa Fluor® 647 anti-mouse F4/80, Pacific Blue™ anti-mouse F4/80, PerCP anti-mouse F4/80, PerCP/Cyanine5.5 anti-mouse F4/80, Alexa Fluor® 700 anti-mouse F4/80, Brilliant Violet 421™ anti-mouse F4/80, Brilliant Violet 510™ anti-mouse F4/80, Alexa Fluor® 594 anti-mouse F4/80, Brilliant Violet 785™ anti-mouse F4/80, Purified anti-mouse F4/80 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse F4/80, Brilliant Violet 650™ anti-mouse F4/80, Brilliant Violet 711™ anti-mouse F4/80, APC/Fire™ 750 anti-mouse F4/80, TotalSeq™-A0114 anti-mouse F4/80, TotalSeq™-B0114 anti-mouse F4/80, TotalSeq™-C0114 anti-mouse F4/80, Spark YG™ 570 anti-mouse F4/80, KIRAVIA Blue 520™ anti-mouse F4/80, Ultra-LEAF™ Purified anti-mouse F4/80, APC/Fire™ 810 anti-mouse F4/80, Spark NIR™ 685 anti-mouse F4/80

## Product Data



Thioglycolate-elicited Balb/c mouse peritoneal macrophages stained with BM8 FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587